NCT02020980

Brief Summary

The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity. Thus, this study will help to expand the information that is available regarding the impact of BoNT-A treatment in routine clinical practice conditions. Treatment goals can vary greatly from one patient to another and there is no unique, single outcome that reflects the treatment benefits in all the cases. Therefore, this study with special focus on the achievement of therapeutic goals, will allow the identification of each patient's specific goals regarding the improvement of the functional outcomes, the quality of life and patient well-being.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
186

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2014

Longer than P75 for all trials

Geographic Reach
1 country

28 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 25, 2013

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2018

Completed
Last Updated

July 29, 2019

Status Verified

July 1, 2019

Enrollment Period

3.9 years

First QC Date

December 19, 2013

Last Update Submit

July 25, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Pain relief on Numeric Rating Scale

    Pain relief evaluated by Numeric Rating Scale (NRS). The NRS score for patient self-reporting of pain ranging from 0 (no pain) to 10 (the most severe pain).

    Baseline visit and every 4 months up to 16 months (Visit 5).

Secondary Outcomes (2)

  • Change in Pain relief on Visual Assessment Scale

    Baseline visit and every 4 months up to 16 months (Visit 5).

  • Responder rate using goal Attainment Scale

    Every 4 months up to 16 months (Visit 5).

Study Arms (1)

Post-stroke lower limb spasticity patients

Biological: Botulinum toxin type A

Interventions

This is an observational study designed to reflect the clinical practice in real life as closely as possible. Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines.

Also known as: AbobotulinumtoxinA (Dysport®)
Post-stroke lower limb spasticity patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients with post-stroke lower limb spasticity in Rehabilitation and Neurology Units of hospitals.

You may qualify if:

  • Men or women age 18 years and above
  • Post-stroke lower-limb spasticity
  • Prior agreement with the patient to inject BoNT-A
  • Therapeutic goals agreed jointly with the patient
  • Functional Ambulation Classification (FAC) score 2-5
  • Capacity to comply with the protocol
  • Written informed consent

You may not qualify if:

  • Documented positive antigenicity to botulinum toxin
  • Neuromuscular disease
  • Use of medications that interfere with neuromuscular transmission
  • Severe muscle atrophy in any muscle to be injected
  • Any other indication that might interfere with rehabilitation or the evaluation of results
  • Any non-stroke spasticity diagnosis
  • Pregnancy or nursing mothers
  • Previous participation in any study using Goal Attainment Scale (GAS)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (28)

Hospital Marítimo Oza

A Coruña, Spain

Location

Hospital General de Albacete

Albacete, Spain

Location

Hospital de Basurto

Bilbao, Spain

Location

Hospital de Cruces

Bilbao, Spain

Location

Hospital de Galdácano

Bilbao, Spain

Location

Hospital Gorliz

Bilbao, Spain

Location

Hospital Guadalajara

Guadalajara, Spain

Location

Hospital Dr Negrín

Las Palmas de Gran Canaria, Spain

Location

Hospital Insular

Las Palmas de Gran Canaria, Spain

Location

Hospital San Pedro

Logroño, Spain

Location

Fundación Jimenez Díaz

Madrid, Spain

Location

Hospital 12 Octubre

Madrid, Spain

Location

Hospital Alcorcón

Madrid, Spain

Location

Hospital General de Móstoles

Madrid, Spain

Location

Hospital Principe de Asturias de Alcalá de Henares

Madrid, Spain

Location

Hospital Universitario de la Princesa

Madrid, Spain

Location

Hospital Ourense

Ourense, Spain

Location

Hospital Son Espases

Palma de Mallorca, Spain

Location

Clinica Ubarmin

Pamplona, Spain

Location

Hospital Virgen de la Vega

Salamanca, Spain

Location

Hospital de Donosti

San Sebastián, Spain

Location

Hospital de la Candelaria

Santa Cruz de Tenerife, Spain

Location

Hospital Universitario Canarias

Santa Cruz de Tenerife, Spain

Location

Hospital Virgen de la Salud

Toledo, Spain

Location

Hospital Reina Sofía

Tudela, Spain

Location

Hospital Clinico Valladolid

Valladolid, Spain

Location

Hospital Xeral de Vigo

Vigo, Spain

Location

Hospital Universitario de Alaba

Vitoria-Gasteiz, Spain

Location

MeSH Terms

Interventions

Botulinum Toxins, Type AabobotulinumtoxinA

Intervention Hierarchy (Ancestors)

Botulinum ToxinsMetalloendopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloproteasesBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsBacterial ToxinsToxins, BiologicalBiological Factors

Study Officials

  • Ipsen Medical Director

    Ipsen

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2013

First Posted

December 25, 2013

Study Start

April 1, 2014

Primary Completion

March 5, 2018

Study Completion

March 5, 2018

Last Updated

July 29, 2019

Record last verified: 2019-07

Locations